People living with established atherosclerotic heart disease who received a shingles vaccine experienced nearly half the rate of serious heart-related events within a year compared with those who were not vaccinated, according to compelling new research. These significant findings are slated for presentation at the American College of Cardiology’s Annual Scientific Session (ACC.26), underscoring a potentially vital, yet underutilized, strategy for cardiovascular risk reduction. The study adds to a growing body of evidence suggesting that the vaccine’s protective benefits extend far beyond the prevention of shingles itself, potentially offering a crucial defense against a range of serious conditions, including heart disease and even neurological disorders like dementia. The Research Unveiled at ACC.26: A Deep Dive into Cardioprotection The study, led by Robert Nguyen, MD, a resident physician at the University of California, Riverside, meticulously reviewed de-identified health data from over 246,822 adults across the United States. All participants had a confirmed diagnosis of atherosclerotic heart disease, a pervasive condition characterized by the dangerous accumulation of plaque within the arteries, which can lead to heart attacks, strokes, and other severe cardiovascular complications. The core revelation from this large-scale analysis is the substantial cardioprotective effect observed in vaccinated individuals within this high-risk population. Dr. Nguyen emphasized the cumulative evidence supporting the vaccine’s broader benefits. "This vaccine has been found over and over again to have cardioprotective effects for reducing heart attack, stroke and death," he stated. "Looking at the highest risk population, those with existing cardiovascular disease, these protective effects might be even greater than among the general public." This sentiment highlights a critical shift in understanding, moving beyond the vaccine’s primary role in preventing herpes zoster to recognizing its potential as a multifaceted public health tool. The presentation of these findings at ACC.26, one of the premier cardiovascular conferences globally, signifies their importance within the cardiology community, bringing a new dimension to discussions on preventive strategies for heart disease. Key Findings: A Striking Reduction in Cardiovascular Risk The researchers focused on heart-related outcomes occurring between one month and one year after vaccination, comparing these with a similar timeframe for the unvaccinated control group. The results were remarkably consistent and statistically significant across all measured parameters. Vaccinated individuals demonstrated a 46% lower likelihood of experiencing a major adverse cardiac event (MACE), a composite endpoint often including heart attack, stroke, and cardiovascular death. Furthermore, the all-cause mortality rate in the vaccinated group was a striking 66% lower. Delving into specific outcomes, the study revealed a 32% reduction in the risk of heart attack, a 25% reduction in the risk of stroke, and a 25% reduction in the risk of heart failure among those who received the shingles vaccine. These are not incremental improvements but substantial reductions that Dr. Nguyen likened to the benefits derived from major lifestyle interventions. "These reductions are substantial and comparable to the benefits seen from quitting smoking," he noted, underscoring the profound impact the vaccine could have on patient prognoses and public health. This level of risk reduction provides a powerful new rationale for promoting shingles vaccination, particularly among individuals already grappling with the challenges of heart disease. Understanding the Cardioprotective Mechanism: Bridging Shingles and Heart Health The Centers for Disease Control and Prevention (CDC) strongly recommends the shingles vaccine for all adults aged 50 years and older, as well as for younger individuals with compromised immune systems. Shingles, or herpes zoster, manifests as a painful rash and can lead to long-lasting nerve pain known as postherpetic neuralgia (PHN). It arises from the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox, which lies dormant in nerve cells for decades after the initial infection. The mechanism by which shingles infection can heighten cardiovascular risk has become clearer through prior research. A shingles outbreak is not merely a localized skin condition; it represents a systemic inflammatory response. The viral reactivation can trigger widespread inflammation throughout the body, including the vasculature. This inflammation can lead to endothelial dysfunction, a condition where the inner lining of blood vessels becomes impaired, promoting the formation of blood clots. Studies have shown that shingles infections can precipitate the formation of dangerous blood clots near vital organs, including the brain and heart, thereby significantly increasing the immediate and short-term risk of heart attacks, strokes, and venous thromboembolism (VTE). By effectively preventing a shingles outbreak, the vaccine is hypothesized to interrupt this inflammatory cascade, thus mitigating the subsequent risk of these dangerous clotting events and other cardiovascular complications. This indirect protective effect underscores the vaccine’s potential as a powerful tool in primary and secondary prevention of cardiovascular disease. A Broader Public Health Perspective: The Burden of Shingles and Heart Disease Shingles is a common and often debilitating condition. The CDC estimates that approximately one in three people in the United States will develop shingles in their lifetime. There are an estimated 1 million cases of shingles annually in the U.S. alone. The risk and severity of shingles, along with its complications like PHN, increase significantly with age. For individuals already living with chronic conditions such as heart disease, the added burden of shingles, coupled with its potential to exacerbate underlying cardiovascular issues, presents a considerable health threat. Globally, cardiovascular disease remains the leading cause of death, claiming an estimated 17.9 million lives each year. Atherosclerotic heart disease is a major contributor to this burden. Therefore, any intervention that can substantially reduce cardiovascular events, especially in a high-risk population, carries immense public health implications. The shingles vaccine, particularly the recombinant zoster vaccine (RZV), Shingrix, boasts an efficacy rate of over 90% in preventing shingles in adults aged 50 and older, and over 85% in preventing PHN. Its high efficacy, combined with the new findings on cardioprotection, positions it as an even more critical component of preventive health strategies. The economic implications are also noteworthy; preventing a heart attack or stroke not only saves lives and improves quality of life but also significantly reduces healthcare costs associated with acute care, rehabilitation, and long-term management of cardiovascular events. The Evolution of Shingles Vaccination and Current Guidelines The journey of shingles vaccination began with Zostavax, a live attenuated vaccine approved in 2006. While effective, its efficacy waned over time and was lower in older adults. The landscape dramatically shifted with the introduction of Shingrix, a recombinant subunit vaccine, in 2017. Shingrix has demonstrated superior efficacy and durability, leading to its widespread recommendation by health authorities. The CDC’s Advisory Committee on Immunization Practices (ACIP) now preferentially recommends Shingrix for immunocompetent adults aged 50 years and older, with a two-dose series. These guidelines were established primarily based on the vaccine’s ability to prevent shingles and its painful sequelae. The new research from ACC.26 provides a compelling additional layer of evidence, reinforcing the rationale for widespread adoption of these existing recommendations. Methodological Rigor and Data Insights from a Large-Scale Database To execute this robust study, researchers leveraged TriNetX, a vast federated research network that aggregates de-identified electronic medical records from millions of Americans across various healthcare organizations. This expansive database allowed for the analysis of a large and diverse cohort, enhancing the generalizability of the findings. The study specifically examined adults aged 50 years or older with atherosclerotic disease between the years 2018 and 2025. The analytical cohort comprised 123,411 individuals who had received at least one dose of either the Shingrix or Zostavax vaccine, meticulously matched with an equal number of unvaccinated individuals. Crucially, the two groups were balanced in terms of key demographic characteristics, including age, sex, race, and ethnicity. Furthermore, researchers adjusted for a comprehensive array of other health conditions (comorbidities) and socioeconomic factors, such as issues related to housing and economic circumstances, social environment, employment status, education, and literacy. This rigorous matching and adjustment process aimed to minimize confounding variables, ensuring that the observed differences in cardiovascular outcomes could be more confidently attributed to vaccination status rather than other health or lifestyle disparities. Despite the inherent limitations of observational studies, the large sample size and sophisticated statistical approach employed in this research provide strong evidence of a meaningful association between shingles vaccination and reduced heart risk. Reinforcing Existing Guidelines and Clinical Implications for Practice The findings from Dr. Nguyen’s team strongly reinforce current public health recommendations regarding shingles vaccination. For clinicians, this research provides an additional, powerful talking point to encourage vaccination among eligible patients, particularly those with existing cardiovascular disease. In an era where vaccine hesitancy and misinformation pose significant public health challenges, such robust evidence of broader health benefits can be instrumental. "Vaccines are one of the most important medicines we have to prevent disease," Dr. Nguyen affirmed. "Sometimes patients are unsure about whether they should get a vaccine or not, particularly in an age of disinformation. These results provide another reason for them to elect to get the vaccine." The American College of Cardiology, through its scientific sessions, often serves as a platform to disseminate such clinically relevant findings, which can directly influence clinical practice guidelines and patient counseling. The implication is clear: routine shingles vaccination should now be considered not just a defense against a painful rash, but a component of a holistic strategy for cardiovascular prevention, especially for vulnerable populations. Beyond the First Year: Long-Term Outlook and Future Research Directions One acknowledged limitation of the current analysis is its focus on outcomes tracked during the first year after vaccination. While this provides critical short-term data, the long-term effects warrant further investigation. However, previous research offers promising insights into extended benefits. A study published in 2025 indicated that shingles vaccination was associated with a 23% reduction in cardiovascular events in generally healthy adults, with benefits potentially lasting up to eight years. This suggests that the protective effects observed in the current study for high-risk cardiac patients could also be sustained over a longer duration. Future research will undoubtedly delve deeper into the precise mechanisms underlying this cardioprotection, potentially exploring specific biomarkers of inflammation or thrombogenesis. Further studies could also investigate the benefits across different subgroups of cardiovascular patients, those with specific comorbidities, or those on particular medications. Additionally, prospective randomized controlled trials, while challenging to conduct for vaccine outcomes, could provide the highest level of evidence. Cost-effectiveness analyses, incorporating the newly identified cardiovascular benefits, would also be valuable for health policy decision-makers. Addressing Limitations and Nuances in Observational Data While the study offers compelling evidence, it is crucial to acknowledge the inherent limitations of observational research. The "healthy user bias" is a common concern in such studies, where individuals who choose to receive vaccines may also be more health-conscious overall, engaging in healthier behaviors, adhering better to medical advice, and having greater access to healthcare. Although the researchers made extensive adjustments for a wide array of demographic, health, and socioeconomic factors, it remains a possibility that some residual confounding might exist. However, the sheer size of the study population, the careful matching of vaccinated and unvaccinated groups, and the comprehensive statistical adjustments significantly strengthen the findings. The consistency of the risk reductions across multiple cardiovascular endpoints also lends credibility to the association. The study’s conclusion, that shingles vaccination is associated with a meaningful reduction in heart risk, stands as a powerful call to action for both patients and healthcare providers. Dr. Nguyen’s presentation, "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease," is scheduled for Monday, March 30, at 12:30 p.m. CT / 17:30 UTC in Posters, Hall E at ACC.26. The findings are expected to stimulate further discussion and research into the multifaceted benefits of routine adult immunizations. Post navigation Nanoscale Architecture, Not Just Ingredients, Dictates Vaccine Potency in a Breakthrough for Cancer Immunotherapy
